Chiara Braconi
University of Glasgow
GeneCancerInternal medicinePathologyOncologymicroRNAMolecular biologyGene expression profilingNon-coding RNAChemotherapyCetuximabPancreatic cancerGemcitabineCancer researchColorectal cancerClinical trialCarcinogenesisBioinformaticsRNAMedicineCell cultureBiologyGastroenterology
121Publications
29H-index
4,872Citations
Publications 129
Newest
#1Pietro Carotenuto (ICR: Institute of Cancer Research)H-Index: 9
#2Francesco Amato (Glas.: University of Glasgow)H-Index: 2
Last. Francesco Sclafani (The Royal Marsden NHS Foundation Trust)H-Index: 22
view all 38 authors...
FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of miRNAs (MIR) as modulators of chemosensitivity to identify potential biomarkers of response. We find that 41 and 84 microRNA inhibitors enhance the sensitivity of Capan1 and MiaPaCa2 PDAC cells respectively. These include a MIR1307-inhibitor that we validate in further PDAC cell l...
Source
#1Alexa Childs (Royal Free London NHS Foundation Trust)H-Index: 6
#2Nekisa Zakeri (Royal Free London NHS Foundation Trust)H-Index: 3
Last. Sam Khan (University Hospitals of Leicester NHS Trust)
view all 19 authors...
BACKGROUND Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 2017, The National Institute for Clinical Excellence mandated histological confirmation of disease to authorise the use of sorafenib in the UK. METHODS This was a prospective multicentre audit in which patients suitable for sorafenib were identified at...
Source
#1Elizabeth C. Smyth (Cambridge University Hospitals NHS Foundation Trust)H-Index: 26
#2Georgios Vlachogiannis (ICR: Institute of Cancer Research)H-Index: 9
Last. Nicola Valeri (ICR: Institute of Cancer Research)H-Index: 32
view all 33 authors...
Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cfDNA) of patients enrolled in a randomised first-line phase III clinical trial of chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab in aGEA (NCT00824785). Design EGFR CN b...
Source
Source
Source
#1Jose J.G. Marin (ISCIII: Carlos III Health Institute)H-Index: 59
#2Maria Giuseppina Prete (Glas.: University of Glasgow)H-Index: 2
Last. Pedro M. Rodrigues (UPV/EHU: University of the Basque Country)H-Index: 7
view all 24 authors...
Source
#1Andrea Lampis (ICR: Institute of Cancer Research)H-Index: 20
#2Jens C. Hahne (ICR: Institute of Cancer Research)H-Index: 24
Last. Paul G. Horgan (Glas.: University of Glasgow)H-Index: 61
view all 18 authors...
Junctional adhesion molecules (JAMs) play a critical role in cell permeability, polarity and migration. JAM-A, a key protein of the JAM family, is altered in a number of conditions including cancer; however, consequences of JAM-A dysregulation on carcinogenesis appear to be tissue dependent and organ dependent with significant implications for the use of JAM-A as a biomarker or therapeutic target. Here, we test the expression and prognostic role of JAM-A downregulation in primary and metastatic ...
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Salvatore PaiellaH-Index: 24
Last. Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 17
view all 18 authors...
PURPOSETo analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC).MATERIALS AND METHODSWe conducted a systematic review and meta...
Source
#1Jens C. Hahne (ICR: Institute of Cancer Research)H-Index: 24
#2Andrea Lampis (ICR: Institute of Cancer Research)H-Index: 20
Last. Matteo Fassan (UNIPD: University of Padua)H-Index: 66
view all 11 authors...
Introduction: Monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) such as cetuximab or panitumumab are used for the treatment of metastatic colorectal cancer (mCRC) patients. Unfortunately, most patients develop resistance against these therapies within months. Several studies have shown that aberrations in the RAS pathway are responsible for resistance. However, even in metastases that are refractory to anti-EGFR treatment a significant fraction of RAS wild-type (wt) cells...
Source
#1Angela Lamarca (University of Manchester)H-Index: 22
#2Alvaro Santos-Laso (UPV/EHU: University of the Basque Country)H-Index: 11
Last. Juan W Valle (University of Manchester)H-Index: 61
view all 18 authors...
BACKGROUND Intrahepatic cholangiocarcinoma (iCCA) with liver metastases (LM) are perceived to have a poor prognosis but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. METHODS Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCCv.7) data were eligible. Modified staging was used (mAJCC...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.